| 曾雅婕,蒋柳宏,赵波,等.血清膜联蛋白 A2与口腔鳞癌病人放化疗敏感性及预后的关系[J].安徽医药,2022,26(10):2049-2052. |
| 血清膜联蛋白 A2与口腔鳞癌病人放化疗敏感性及预后的关系 |
| Relationships between serum annexin A2 and chemosensitivity and prognosis of patients with oral squamous cell carcinoma |
| |
| DOI：10.3969/j.issn.1009-6469.2022.10.033 |
| 中文关键词: 口腔肿瘤 癌，鳞状细胞 膜联蛋白 A2 临床病理参数 放化疗敏感性 预后 |
| 英文关键词: Mouth neoplasms Carcinoma,squamous cell Annexin A2 Clinicopathological parameters Chemoradiotherapy sensitivity Prognosis |
| 基金项目: |
|
| 摘要点击次数: 757 |
| 全文下载次数: 234 |
| 中文摘要: |
| 目的分析血清膜联蛋白 A2(ANXA2)在中晚期口腔鳞癌( OSCC)病人中的表达，并探讨其与放化疗敏感性及预后的关系。方法将 2013年 2月至 2015年 2月广州中医药大学第一附属医院收治的 68例中晚期 OSCC病人纳入为研究组，另将 68例同期体检健康者为对照组， OSCC病人行放化疗治疗，收集受试者血清，采用酶联免疫吸附法( ELISA)检测血清 ANXA2水平，比较两组血清 ANXA2水平，与病理参数、放化疗敏感性及预后的关系。结果研究组病人血清 ANXA2水平( 28.15±6.24) μg/L明显高于对照组( 13.92±4.18)μg/L(P<0.05)；血清 ANXA2表达与 OSCC病人年龄、性别、肿瘤大小无关( P>0.05)，与 TNM分期、分化程度、淋巴结转移、远处转移相关( P<0.05)； ANXA2高表达组病人放化疗总有效率为 54.84%，明显低于 ANXA2低表达组病人总有效率的 78.38%(P<0.05)； OSCC病人血清 ANXA2低表达病人 5年中位数生存时间为(37.00±5.28)个月，高表达组 5年中位数生存时间为( 28.00±3.89)个月，两组病人预后 5年中位数生存时间比较差异有统计学意义( P<0.05)。结论 OSCC病人血清 ANXA2高表达，并与 TNM分期、分化程度、淋巴结转移、远处转移相关， ANXA2高表达者的放化疗敏感性低，预后差。 |
| 英文摘要: |
| Objective To analyze the expression of serum annexin A2 (ANXA2) in patients with advanced oral squamous cell carci.noma (OSCC), and to explore its relationship with chemosensitivity and prognosis.Methods Sixty-eight patients with advanced OSCCadmitted to The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine from February 2013 to February2015 were included as the study group, and 68 healthy people in the same period were selected as the control group. OSCC patientswere treated with radiotherapy and chemotherapy, serum of whom was collected, and enzyme-linked immunosorbent assay (ELISA) wasused to detect serum ANXA2 level. The relationships between serum ANXA2 level with pathological parameters, chemoradiotherapysensitivity, and prognosis were compared between the two groups.Results The serum ANXA2 level of the study group was significant. ly higher than that of the control group [(28.15±6.24) μg/L vs. (13.92±4.18) μg/L; P<0.05]. The serum expression of ANXA2 was not correlated with age, gender, and tumor size of OSCC patients (P>0.05), but correlated with TNM staging, differentiation degree, lymph node metastasis, and distant metastasis (P<0.05). The total effective rate of chemoradiation in patients with high ANXA2 expression was 54.84%, which was significantly lower than 78.38% in patients with low ANXA2 expression (P<0.05). The 5-year median survivaltime of OSCC patients with low ANXA2 expression was (37.00±5.28) months, and that of patients with high ANXA2 expression was(28.00±3.89) months; there was significant difference between the two groups (P<0.05).Conclusion The serum ANXA2 is highly ex.pressed in OSCC patients, and is associated with TNM staging, differentiation, lymph node metastasis, and distant metastasis. Patientswith high expression of ANXA2 have low sensitivity to chemoradiotherapy and poor prognosis. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
